Chronic Kidney Disease

>

Latest News

US FDA logo in black over a white background. | Credit: US Food and Drug Administration
FDA Committee Casts Negative Vote on Sotagliflozin in Type 1 Diabetes

November 2nd 2024

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

Depagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
Dapagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease

October 26th 2024

Katherine R. Tuttle, MD, Clinical Professor of Medicine, University of Washington Medicine, and Executive Director for Research, Providence Health Care, and Regional Co-Principal Investigator, Institute of Translational Health Sciences, Providence Medical Research Center
Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities

October 26th 2024

Hiddo Heerspink, PharmD, PhD | Credit: George Institute for Global Health
Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease

October 25th 2024

Will Herrington, MA, MBBS, MD, FRCP, FERA, Professor of Trials and Epidemiology of Kidney Disease, Renal Studies Group, Nuffield Department of Population Health, and practicing Honorary Consultant Nephrologist, Oxford Kidney Unit, Oxford University
Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation

October 25th 2024

<1
...
45678
© 2024 MJH Life Sciences

All rights reserved.